Patents by Inventor Mitsuaki Isobe

Mitsuaki Isobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GRAFT REJECTION SUPPRESSORS
    Publication number: 20090047292
    Abstract: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 12, 2008
    Publication date: February 19, 2009
    Applicant: Japan Tobacco, Inc.
    Inventors: Seiichi Suzuki, Atsuko Suzuki, Mitsuaki Isobe
  • Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis
    Publication number: 20080269247
    Abstract: The present invention relates to piperazine derivatives of formulae Ia, Ib, Ic and Id and their use to treat myocarditis. where R1a, R1b, R2, R3, R4, R5, R6, R9, R10 and Y are as defined herein.
    Type: Application
    Filed: August 6, 2007
    Publication date: October 30, 2008
    Inventors: Hideki Futamatsu, Mitsuaki Isobe, Noritaka Koga, Jun-ichi Suzuki, William Dole
  • Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
    Patent number: 7438905
    Abstract: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: October 21, 2008
    Assignee: Japan Tobacco, Inc.
    Inventors: Atsuko Suzuki, legal representative, Mitsuaki Isobe, Seiichi Suzuki
  • Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
    Publication number: 20050043318
    Abstract: The present invention relates to piperazine derivatives of formulae Ia, Ib, Ic and Id and their use to treat myocarditis. where R1a, R1b, R2, R3, R4, R5, R6, R9, R10 and Y are as defined herein.
    Type: Application
    Filed: August 20, 2004
    Publication date: February 24, 2005
    Applicants: Schering Aktiegesellschaft, Tokyo Medical and Dental University
    Inventors: Hideki Futamatsu, Mitsuaki Isobe, Noritaka Koga, Jun-ichi Suzuki, William Dole
  • Graft rejection suppressors
    Publication number: 20040253229
    Abstract: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 16, 2004
    Inventors: Seiichi Suzuki, Mitsuaki Isobe, Atsuko Suzuki
  • Agents inhibiting chronic rejection reactions after organ transplantation
    Patent number: 6552083
    Abstract: The present invention relates to an agent for inhibiting diseases associated with chronic rejection after organ transplantation, such as transplanted heart-accelerated coronary arteriosclerosis, containing as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by formula: or a pharmaceutically acceptable salt thereof, which has an inhibitory effect on vascular thickening in transplanted hearts.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: April 22, 2003
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Mitsuaki Isobe, Atsushi Izawa
  • Induction of tolerance with modified immunogens
    Patent number: 5885570
    Abstract: A method is provided for inducing tolerance to T-cell mediated immunity. Particularly, tolerance is induced in a recipient mammal to a transplanted organ or tissue. Tolerance is induced by treating the recipient mammal with a MHC antigen which has been modified to render an immunosuppressive effect.
    Type: Grant
    Filed: January 23, 1991
    Date of Patent: March 23, 1999
    Assignee: The General Hospital Corporation
    Inventors: Mitsuaki Isobe, Ban An Khaw, Philip D. Nicol
  • Method for early detection of allograft rejection
    Patent number: 5223241
    Abstract: The invention relates to a method of detecting early rejection of an allograft in a mammal by administering to the mammal a diagnostically effective amount of detectably labeled immunoglobulin or fragment thereof, wherein the immunoglobulin substantially accumulates at the site of allograft rejection. The method of the invention may also be used to monitor allograft rejection during immunosuppressive therapy in a mammal which has received an allograft or to localize areas involved in autoimmune disease or inflammation.
    Type: Grant
    Filed: August 16, 1991
    Date of Patent: June 29, 1993
    Assignees: The General Hospital Corporation, Bristol-Myers Squibb Company
    Inventors: Mitsuaki Isobe, Ban A. Khaw, Edgar Haber